MDCO - The Medicines Company

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

The Medicines Company

8 Sylvan Way
Parsippany, NJ 07054
United States
973-290-6000
http://www.themedicinescompany.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees410

Key Executives

NameTitlePayExercisedAge
Dr. Fredric N. Eshelman Pharm.D.Exec. Chairman78.29kN/A68
Dr. Clive A. Meanwell M.D., Ph.D.CEO & Director1.75M824.05k59
Mr. Stuart Anthony Kingsley MBAPres and Chief Operating Officer723.78kN/A53
Mr. William B. O'ConnorChief Financial Officer863.37kN/A58
Mr. Stephen M. Rodin J.D.Exec. VP, Gen. Counsel and Sec.798.42kN/A41
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms. The company’s approved products include Adenosine, Amiodarone, Esmolol, and Milrinone for acute cardiovascular; Azithromycin and Clindamycin for serious infectious disease; and Haloperidol, Midazolam, Ondansetron, and Rocuronium for surgery and perioperative treatment. Its research and development stage products comprise Carbavance, an antibiotic agent that has completed Phase III development stage for the treatment of hospitalized patients with serious gram-negative bacterial infections; Inclisiran, a synthesis inhibitor for the potential treatment of hypercholesterolemia; and MDCO-700, an intravenous anesthetic agent developed for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures. The Medicines Company has a collaboration agreement with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

Corporate Governance

The Medicines Company’s ISS Governance QualityScore as of December 1, 2017 is 4. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.